Current Possibilities of Application

In all fields of medicine, uses for stem cells are being researched or even today being used clinically as treatment attempt in order to heal defective tissues or grow replacement tissue.

TICEBA - Current possibilities of application - ABCB5


Current Fields of Application

  • In cardiology, stem cell therapy following heart attacks has already entered daily routine.
  • The growth or reproduction of skin cells and chondrocytes has become a routine procedure in medicine today in order to cover major skin or cartilage defects in the joint area.
  • In laboratory conditions, kidney cells were manufactured using the tissue engineering and their functionality has been proven. Furthermore, other spare organs or parts are already being grown in laboratory conditions and are used in animal research experiments.

Please find additional valuable information about the technology progress within our literature.

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients infected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter